Patients with clinically indicated hormone deficiencies may also benefit from separate hormone evaluation, which is not a weight-loss therapy but can be part of comprehensive metabolic care
The full weight loss trajectory continues to improve through 72 weeks and beyond with consistent use
The STEP clinical trial program, which evaluated semaglutide at the 2.4mg weekly dose for weight management, provides the most robust data
Mandelbaum points out that the link between obesity and osteoarthritis is multifactorial. There are genetic aspects, physical aspects, and inflammatory aspects, he says
Another significant benefit of the medication class is its ability to reduce cardiovascular risk in patients with type 2 diabetes
Similar to other GLP-1, GIP stimulates insulin secretion in hyperglycemic states